Trials / Completed
CompletedNCT01344876
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose (MTD) of OPB-51602
Conditions
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Chronic Myeloid Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPB-51602 | once daily during the treatment period |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2011-04-29
- Last updated
- 2015-06-08
- Results posted
- 2015-06-08
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01344876. Inclusion in this directory is not an endorsement.